selexipag - Profile

What are the generic drug sources for selexipag and what is the scope of freedom to operate?

Selexipag is the generic ingredient in two branded drugs marketed by Actelion, Alembic, and Zydus Lifesciences, and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selexipag has one hundred and seventy-seven patent family members in forty-two countries.

There are two tentative approvals for this compound.

Summary for selexipag

International Patents:	177
US Patents:	6
Tradenames:	2
Applicants:	3
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for selexipag

Generic filers with tentative approvals for SELEXIPAG

Applicant	Application No.	Strength	Dosage Form
		1.6MG	TABLET;ORAL
		1.4MG	TABLET;ORAL
		1.2MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for SELEXIPAG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
UPTRAVI	For Injection	selexipag	1.8 mg/vial	214275	1	2022-07-29
UPTRAVI	Tablets	selexipag	0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg and 1.6 mg	207947	4	2019-12-23

US Patents and Regulatory Information for selexipag

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes					Y
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes					Y
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes					Y
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes					Y
Alembic	SELEXIPAG	selexipag	TABLET;ORAL	214414-001	Oct 11, 2023	AB	RX	No	No
Alembic	SELEXIPAG	selexipag	TABLET;ORAL	214414-002	Oct 11, 2023	AB	RX	No	No
Alembic	SELEXIPAG	selexipag	TABLET;ORAL	214414-003	Oct 11, 2023	AB	RX	No	No

EU/EMA Drug Approvals for selexipag

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen Cilag International NV	Uptravi	selexipag	EMEA/H/C/003774Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,	Authorised	no	no	no	2016-05-12

International Patents for selexipag

Country	Patent Number	Title	Estimated Expiration
Slovenia	3275871
Spain	2797124
Portugal	2447254
Argentina	121658
Peru	20181072	COMPOSICION FARMACEUTICA QUE CONTIENE 2-{4-[N-(5,6-DIFENILPIRAZIN-2-IL)-N-ISOPROPILAMINO]BUTILOXI}-N-(METILSULFONIL)ACETAMIDA
Denmark	4331607
Brazil	112018009534

Supplementary Protection Certificates for selexipag

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1400518	CR 2016 00048	Denmark		PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
1400518	CA 2016 00048	Denmark		PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
1400518	300836	Netherlands		PRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
2447254	PA2018008,C2447254	Lithuania		PRODUCT NAME: SELEKSIPAGAS; REGISTRATION NO/DATE: EU/1/15/1083 20160512
2447254	2018015	Norway		PRODUCT NAME: 2-4-(N-(5,6-DIFENYLPYRAZIN-2- YL)-N- ISOPROPYLAMINO)BUTYLOKSY-N-; REG. NO/DATE: EU/1/15/1083 20160530
1400518	44/2016	Austria		PRODUCT NAME: SELEXIPAG ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083 (MITTEILUNG) 20160519
1400518	2016/047	Ireland		PRODUCT NAME: SELEXIPAG OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1083 20160512

Selexipag: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Selexipag (trade name: Uptravi) is an oral prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH). Its market positioning, driven by expanding indications and increased prevalence of PAH, presents potential opportunities and risks for investors. This report analyzes market dynamics, competitive landscape, regulatory environment, key financial metrics, and future growth trajectories. It also provides strategic insights into the investment potential for stakeholders.

Market Overview and Pharmacological Profile

Parameter	Details
Indication	Pulmonary arterial hypertension (PAH)
Mechanism	Selective prostacyclin receptor (IP receptor) agonist
Approval Date	March 2015 (FDA), EU 2016
Pharmacodynamics	Improves vasodilation, inhibits smooth muscle proliferation, reduces pulmonary vascular resistance
Pricing (Approximate)	$7,000–$8,000/month (U.S. market)

Selexipag operates within a niche market targeting PAH, a progressive, life-threatening condition with a global prevalence estimated at ~15-50 per million [1]. The drug's unique mechanism positions it among selective IP receptor agonists, competing with prostacyclin analogs and other vasodilators.

Market Dynamics

Key Drivers

• Growing Prevalence of PAH: Increased diagnosis rates, improved screening programs, and aging populations drive market growth.
• Expanding Indications: Approval for other forms of pulmonary hypertension (e.g., WHO Group 1 and chronic thromboembolic PH) broadens market reach.
• Pipeline and Label Expansion: Ongoing clinical studies for combination therapies and new indications could extend life cycle.

Market Barriers and Risks

• Pricing and Reimbursement Challenges: High cost and variable payer policies influence adoption.
• Competitive Landscape: Presence of drugs like epoprostenol, riociguat, and macitentan.
• Side Effect Profile: Common adverse events include headache, nausea, and jaw pain, impacting patient adherence.

Competitive Landscape Table

Competitor	Mechanism	Approvals	Market Share (Estimate)	Notable Trials	Price Range (per month)
Epoprostenol	Prostacyclin analog	FDA 1995	25-30%	PHIRST	$20,000+
Riociguat	Soluble guanylate cyclase stimulator	FDA 2013	15-20%	PATENT-1	$10,000–$15,000
Macitentan	Endothelin receptor antagonist	FDA 2013	15%	SERAPHIN	$4,500–$6,000
Selexipag	Prostacyclin receptor agonist	FDA 2015	10-15%	GRIPHON	$7,000–$8,000

Regulatory and Reimbursement Trends

• Global Approvals: Positioned in over 50 countries, with expanding approvals in Asia and Latin America.
• Reimbursement Policies: Variable, with payers in the U.S. and Europe increasingly scrutinizing high-cost therapies. Managed care organizations are negotiating value-based agreements.

Financial Trajectory Analysis

Sales and Revenue Growth

Year	Global Revenue (USD Million)	Growth Rate
2015	$186	—
2016	$430	131%
2017	$845	96%
2018	$1,050	24%
2019	$1,200	14%
2020	$1,350	13%
2021	$1,500	11%
2022	$1,600	7%

This steady revenue growth reflects increasing prescriptions driven by expanding indications and geographic reach.

Cost Structure and Profitability

Cost Component	Approximate Percentage of Revenue	Notes
R&D	10-12%	Focus on pipeline expansion and new indications
Sales & Marketing	20-25%	Key for market penetration
Manufacturing	5-7%	Scalability efforts
Operating Profit Margin	25-30% (2022)	Improved efficiency

Investment and Licensing Deals

• The company has entered various licensing agreements in emerging markets to accelerate access and revenue.
• R&D alliances focused on combination therapies, e.g., with endothelin receptor antagonists, could further augment sales.

Future Market Outlook

Projections hinge on several factors:

• Compound Annual Growth Rate (CAGR) (2023-2028): Estimated at 8-10%, driven by emerging markets and label expansions.
• Market Size: Expected to reach approximately $2.8 billion globally by 2028, given current trends and pipeline progress.
• Patent and Exclusivity: Patent expiry in 2030, with potential for extensions via new formulations or indications.

Key Assumptions	Underpinning Projections
Market Penetration	Continuing uptake in existing markets
New Indications	Expansion into chronic thromboembolic PH
Pricing	Stable or slight increase, offset by payer pressures
Pipeline Success	Positive trial outcomes for combination treatments

Comparative Analysis: Selexipag Versus Competitors

Criterion	Selexipag	Epoprostenol	Riociguat	Macitentan
Administration	Oral	IV or inhaled	Oral	Oral
Ease of Use	High	Low	Moderate	High
Cost	Moderate	High	Moderate	Low
Efficacy	Proven	Proven	Proven	Proven
Side Effects	Headache, nausea	Hemorrhage, infusion site pain	Headache, hypotension	Headache, edema
Market Share (Estimate)	10-15%	25-30%	15-20%	15%

Investment Considerations

Strengths

• Proven efficacy and expanding indication portfolio.
• Growing global footprint.
• Strong current revenue base with potential pipeline catalysts.

Weaknesses

• High competition and pricing pressures.
• Patent expiry risks.
• Market penetration slower in emerging economies.

Opportunities

• Label expansions into other pulmonary hypertension groups.
• Development of combination therapies.
• Strategic alliances to accelerate market access.

Threats

• Biosimilar and generic entrants post-patent expiry.
• Regulatory delays in certain geographies.
• Payer-driven formulary restrictions.

---

Key Takeaways

• Market Positioning: Selexipag remains a key player in PAH, with a robust pipeline and expanding indications.
• Financial Outlook: Steady revenue growth projected at roughly 8-10% CAGR through 2028, driven by worldwide adoption.
• Competitive Edge: Oral administration provides an advantage over IV prostacyclin formulations, facilitating patient compliance.
• Risks: Heightened competition, patent expiries, and reimbursement challenges necessitate strategic planning.
• Investment Threshold: Suitable for investors seeking exposure to specialty pharmaceuticals with growth potential, provided they account for market and regulatory risks.

---

FAQs

1. What are the primary drivers for Selexipag's market growth?
The main drivers include rising prevalence of PAH, expanding indications, increased global approvals, and favorable clinical trial outcomes supporting label extensions.

2. How does Selexipag's efficacy compare to other PAH therapies?
Clinical trials, notably GRIPHON, demonstrate comparable or superior efficacy to existing prostacyclins and vasodilators, with the added convenience of oral administration enhancing patient adherence.

3. What are the key regulatory challenges facing Selexipag?
While current approvals are solid, future label expansions may face regulatory hurdles related to demonstrating safety and efficacy in broader populations, particularly post anti-inflammatory or combination approach studies.

4. How vulnerable is Selexipag to generic entry post-patent expiry?
Patent expiry anticipated around 2030 could open the market to biosimilar or generic competitors, potentially reducing prices and market share unless protected by regulatory exclusivities or new indications.

5. What strategic moves could enhance Selexipag’s market share?
Investment in pipeline development for combination therapies, geographic expansion especially in emerging markets, and engaging with payers via value-based pricing strategies can bolster market position.

---

References

[1] Ryan, J. J., et al. (2013). Pulmonary hypertension: Advances in pathogenesis and treatment. The Medical Clinics of North America, 97(2), 239–256.
[2] Galiè, N., et al. (2015). Selexipag in pulmonary arterial hypertension. The New England Journal of Medicine, 373(26), 2523–2533.
[3] Uptravi (selexipag) product label. (2015). U.S. Food and Drug Administration.
[4] Market research and forecasts by GlobalData, 2022.

---

This comprehensive analysis offers clarity into Selexipag's current positioning and future prospects, informing strategic investment decisions in the pulmonary hypertension therapeutics landscape.